HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Summary

This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents

Timeline

Start

2024-09-03

Primary completion

2025-07-28

Completion

2025-10-03

Outcome

Met primary endpoint

release “磷罗拉匹坦帕洛诺司琼（HR20013）联合地塞米松预防中致吐性化疗引起的恶心呕吐：一项随机、双盲Ⅲ期研究（PROTECT）结果正式亮相口头报告环节（摘要号：11006） [1] 。该研究由中山大学肿瘤防治中心 张力教授、李宇红教授 牵头，全国81家研究中心共同参与。研究结果显示 [1] ，磷罗拉匹坦帕洛诺司琼联合地塞米松组延迟期完全缓解（CR）率为79.0%，显著优于对照组（P<0.001）” hengrui.com ↗

Drugs

Indications